Abstract
These NCCN Guidelines Insights highlight the important updates/changes specific to the management of relapsed or progressive disease in the 2013 version of the NCCN Clinical Practice Guidelines in Oncology for Multiple Myeloma. These changes include the addition of new regimens as options for salvage therapy and strategies to mitigate the adverse effects and risks associated with newer regimens for the treatment of multiple myeloma.
MeSH terms
-
Antineoplastic Agents / adverse effects
-
Antineoplastic Agents / therapeutic use*
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Bendamustine Hydrochloride
-
Boronic Acids / administration & dosage
-
Bortezomib
-
Dexamethasone / administration & dosage
-
Disease Progression
-
Humans
-
Hydroxamic Acids / administration & dosage
-
Lenalidomide
-
Multiple Myeloma / complications
-
Multiple Myeloma / drug therapy*
-
Nitrogen Mustard Compounds / administration & dosage
-
Oligopeptides / therapeutic use
-
Peripheral Nervous System Diseases / etiology
-
Peripheral Nervous System Diseases / therapy
-
Practice Guidelines as Topic*
-
Pyrazines / administration & dosage
-
Recurrence
-
Salvage Therapy*
-
Thalidomide / administration & dosage
-
Thalidomide / analogs & derivatives
-
Vorinostat
Substances
-
Antineoplastic Agents
-
Boronic Acids
-
Hydroxamic Acids
-
Nitrogen Mustard Compounds
-
Oligopeptides
-
Pyrazines
-
Thalidomide
-
Vorinostat
-
Bortezomib
-
carfilzomib
-
Dexamethasone
-
Bendamustine Hydrochloride
-
Lenalidomide